Index
Age-related macular degeneration (AMD) (Continued)

CFI, 133, 135
CFR, 133
-genetic risk scores, 136–137
HTRA1, 129, 134
meta-analysis of studies, 134–135
PLEKHA1, 129
prospects, 135–136

highly penetrant alleles
ARMS2, 155–156
CFH, 155–156, 159–161
HTRA1, 155–156
overview, 155–157

rare variants
ABCA4, 161–162
C3, 158–159
C9, 159
candidate gene analysis, 157–158
CFI, 161
clinical subtypes, 164
exome chip analysis, 158
exome sequencing, 158

linkage analysis, 157
-predictive testing, 163–164
-prospects for study, 164–165
whole genome sequencing, 158

induced pluripotent stem cell modeling, 94–95
-risk factors, 110, 128–129, 170
RNA-Seq studies, 83–84
treatment
-neovascular disease
afliberept, 121
bevacizumab, 121
-combination therapy, 121
-macular surgery, 119–120
pegaptanib, 120
photocoagulation, 119
photodynamic therapy, 120–121
ranibizumab, 120–121
nonneovascular disease, 118–119

AGEs. See Advanced glycation end products
AHI1, genetic modifiers, 62, 64
AIPL1, Leber congenital amaurosis variants, 44
ALMS1
-Alström disease mutations, 101
-inherited retinal degeneration, 46
Alström disease
-clinical features, 101–102
-hearing loss, 100
AMD. See Age-related macular degeneration
Amyloid-β, drusen formation, 149
Angiostatin, gene therapy for age-related macular degeneration, 314–315

ARMS2
-age-related macular degeneration susceptibility studies, 129, 134, 156
-induced pluripotent stem cell modeling of mutation, 95

B
Bardet–Biedl syndrome (BBS)
-clinical features, 103
-gene mutations, 46
-genetic modifiers, 59, 62, 65
-retinitis pigmentosa, 6
Basal lamellar deposits (BLamD), age-related macular degeneration, 111
Bassen–Kornzweig syndrome (BKS), clinical features, 103
BBS. See Bardet–Biedl syndrome
BCD. See Bietti’s crystalline retinal dystrophy
BDNF. See Brain-derived neurotrophic factor
BEST1, induced pluripotent stem cell modeling of mutation, 94
β-Carotene, age-related macular degeneration management, 118
Bevacizumab, age-related macular degeneration management, 121
BF, age-related macular degeneration susceptibility studies, 132
Bietti’s crystalline retinal dystrophy (BCD), clinical features, 104
Bimatoprost, glaucoma management, 201
BKS. See Bassen–Kornzweig syndrome
BLamD. See Basal lamellar deposits
Brain-derived neurotrophic factor (BDNF), neuroprotection, 15
BrainPort, 18

C
CABP4, congenital stationary night blindness mutations, 10
CACD. See Central areolar choroidal dystrophy
CACNA1F, congenital stationary night blindness mutations, 10
CACNA2D4, congenital stationary night blindness mutations, 10
Candidate gene analysis
-age-related macular degeneration susceptibility studies, 157–158
-genetic modifier identification, 62
CAV1, glaucoma mutations, 211–212
CAV2, glaucoma mutations, 211–212
CCDC28B, genetic modifiers, 57–58, 62, 65
CCT. See Central corneal thickness
CDKN2BAS
-glucoma mutations, 211–213, 215
-therapeutic targeting, 255
Central areolar choroidal dystrophy (CACD), clinical features, 104
Central corneal thickness (CCT), glaucoma, 195, 213
CEP290
- genetic modifiers, 56, 64
- inherited retinal degeneration, 44, 46
- mouse model of Leber congenital amaurosis, 416
- mutation effects, 105–106
- pathogenicity of mutations, 50
- retinitis pigmentosa mutations, 6–7
CFB, age-related macular degeneration susceptibility studies, 134
CFD, age-related macular degeneration susceptibility studies, 133
CFG, age-related macular degeneration susceptibility studies, 133
CFH
- drusen formation, 149–150
- genetic modifiers, 59
- induced pluripotent stem cell modeling of mutation, 95
- ligand lipoxidation in drusen, 148
CFHR genes, age-related macular degeneration susceptibility studies, 132
CFI, age-related macular degeneration susceptibility studies, 133, 135, 161
CFP, age-related macular degeneration susceptibility studies, 133
Channel rhodopsin-2 (ChR2), optogenetics, 16–17
CHM
- choroideremia mutations, 10, 42
- gene therapy
  - clinical trials, 284–285
  - overview, 13, 275–277
  - prospects, 285
  - vector
    - design, 280–283
    - preclinical testing of AAV2 vector, 283–284
- protein. See REP1
Choroidal neovascularization (CNV), age-related macular degeneration, 113–116
Choroideremia
CHM gene therapy
- clinical trials, 284–285
- overview, 13, 275–277
- prospects, 285
- vector
  - design, 280–283
  - preclinical testing of AAV2 vector, 283–284
- clinical features, 9–10
- epidemiology, 277
- gene mutations, 275–278
- history of study, 277
molecular diagnosis, 277–278
REP1
- animal mutant studies, 279–280
- expression and function, 278–279
ChR2. See Channel rhodopsin-2
Ciliary neurotrophic factor (CNTF)
- gene therapy, 356
- neuroprotection, 15, 255–256, 376
9-cis-Retinal, Retinal degeneration management
CLN1, neuronal ceroid lipofuscinosis mutation, 103–104
CLN3
- mutation effects, 106
- neuronal ceroid lipofuscinosis mutation, 104
CLRNI, Usher syndrome mutations, 46
CNGA1, retinitis pigmentosa mutations, 5
CNGA3, achromatopsia mutations, 11, 46
CNGB3
- achromatopsia mutations, 11
- gene therapy, 13–14
CNTE. See Ciliary neurotrophic factor
CNV. See Choroidal neovascularization; Copy number variation
COL11A1, glaucoma mutations, 213
COL15A1, genetic testing, 252
COL18A1, genetic testing, 252
Color blindness
- developmental neural plasticity, 401
- gene therapy prospects, 410–411
- mouse trichromacy with M opsin knock-in, 408–409
- squirrel monkey trichromacy
  - biological basis of trichromacy in primates, 406–408
  - evolutionary mechanism of shift from dichromacy, 405, 409
  - gene therapy delivery, 409–410
  - L opsin, 402–405
  - neural networks in newly trichromatic primates, 406
  - neural plasticity, 405–406
  - photopigments, 402
Complement
- activation pathways, 127
- age-related macular degeneration
  - genome-wide association studies in susceptibility
    - ARMS2, 129, 134
    - BF, 132
    - C2, 132, 134
    - C3, 133, 135
    - C5, 133
    - C9, 135
    - CFB, 134
    - CFD, 133

© 2015 by Cold Spring Harbor Laboratory Press. All rights reserved.
Index

Complement (Continued)

CFG, 133
CFH, 129–134
CFHR genes, 132
CFI, 133, 135
CFR, 133

genetic risk scores, 136–137
HTRA1, 129, 134
meta-analysis of studies, 134–135
PLEKHA1, 129
prospects, 135–136

highly penetrant alleles
C3, 158–159
C9, 159
CFH, 155–156, 159–161
CFI, 161

glaucoma cascade, 238–239, 243–245
Cone–rod degenerations/dystrophies (CORDs), overview, 7
Congenital stationary night blindness (CSNB)
clinical features, 10
genetic mutations, 10
Copy number variation (CNV), inherited retinal degeneration, 45–46
CORDs. See Cone–rod degenerations/dystrophies
CRB1, Leber congenital amaurosis variants, 44
CRISPR/Cas system, genome editing, 420–421
CRX
Leber congenital amaurosis mutations, 7
retinitis pigmentosa mutations, 5
CSNB. See Congenital stationary night blindness
CYP1B1
genetic testing, 250–252
   glaucoma expression, 222
   glaucoma mutations, 208, 215
   therapeutic targeting, 255

D

DHA. See Docosahexaenoic acid
DNA microarrays, age-related macular degeneration gene expression studies, 174–176
Docosahexaenoic acid (DHA), retinal degeneration management, 11
Drusen
clinical features, 112, 141
formation, 142, 149
   proteomics studies in age-related macular degeneration
   oxidative protein modifications, 146–149
   prospects, 149–150
   qualitative studies, 142–143
   quantitative studies
   Bruch's membrane/choroid, 143–145
   mouse studies, 144, 146

E

Eculizimab, age-related macular degeneration management, 119
EFEMP1. See Extracellular matrix protein 1
ELAV. See Equine infectious anemia virus
Electroretinogram (ERG)
   achromatopsia findings, 11
   choroideremia findings, 10
   congenital stationary night blindness findings, 10
   Leber congenital amaurosis findings, 7
   retinitis pigmentosa findings, 2–3
   Stargardt disease findings, 8
   X-linked retinoschisis findings, 8, 334–335
Embryonic stem cell (ESC)
cell therapy, 17–18
gene therapy, 416
Endostatin, gene therapy for age-related macular degeneration, 314–315
ENDRA, genetic modifiers, 58
ENDRB, genetic modifiers, 60
Equine infectious anemia virus (EIAV), gene therapy vectors
   endostatin delivery, 315
   MYO7A delivery, 302–303
   overview, 14
ERAP1, genetic modifiers, 70
ERG. See Electroretinogram
ESC. See Embryonic stem cell
EST. See Expressed sequence tags
Estrogen, metabolism and glaucoma, 215
Exome chip analysis, age-related macular degeneration susceptibility studies, 158
Exome sequencing
   age-related macular degeneration susceptibility studies, 158
   next generation sequencing, 44–45
   Expressed sequence tags (EST), overview, 77
Extracellular matrix protein 1 (EFEMP1), 144, 146, 149

F

FAM161A, variant prioritization, 49
Fanconi anemia, gene therapy, 418
FBLN5, age-related macular degeneration susceptibility studies, 162
FCD. See Fuchs corneal dystrophy
FECH, genetic modifiers, 58
FGF. See Fibroblast growth factor
Fibroblast growth factor (FGF), FGF-2 neuroprotection, 15
Fluorescein angiography, choroidal neovascularization, 114
FOX1
   genetic testing, 250–252, 254
   glaucoma mutations, 209
FTO, genetic modifiers, 58

440

© 2015 by Cold Spring Harbor Laboratory Press. All rights reserved.
Fuchs corneal dystrophy (FCD), genetic modifiers, 60
Fundus autofluorescence
  retinitis pigmentosa findings, 2–3
  Stargardt disease findings, 8–9

G
Gene therapy. See also specific diseases and genes
  economic considerations, 432–433
  efficacy improvement, 429–431
  indications, 12–14
  limitations, 431–432
  outcome measures, 432
  prospects, 433
  success stories, 427–429
  vectors, 12–13
Genetic modifiers
  cloning strategies
    candidate gene approach, 62
    candidate locus association studies, 60, 62
    linkage analysis, 60
    mouse strain studies, 63–64
    overview, 60–61
    system-based candidates, 62
    transcriptome analysis, 62–63
    whole-exome data in toto, 63
identification challenges
  nongenetic factors, 59–60
  study availability, 59
overview, 55–56
properties
  allelic heterogeneity, 56
  locus sharing with disease driver, 58
  multiple interactions, 56–58
  variant frequency in general population, 58–59
prospects for study, 70–71
retinal degeneration studies
  humans, 64–65, 67–68
  mice, 66, 68–70
Genome editing, induced pluripotent stem cells, 419–421
Geographic atrophy, age-related macular degeneration, 112–114
GFAP. See Glial fibrillary acidic protein
Glaucoma
  etiology, 192–193
  gene expression studies
    anterior eye, 222
    ganglion cell central projecting targets, 228
    optic nerve, 225–228
    overview, 221–222
    prospects for study, 228–229
    retina, 222–225
  genetics
    adult-onset glaucoma
      normal-tension glaucoma, 212
    overview, 211–212
    primary open-angle glaucoma, 213
    pseudoexfoliation syndrome, 212–213
    qualitative ocular traits as risk factors, 213
    complex interactions, 213–214
    early-onset disease
      congenital glaucoma, 208–209
      developmental glaucoma, 209
      juvenile-onset primary open-angle
        glaucoma, 209–211
      normal-tension glaucoma, 211
      overview, 207–208
    estrogen metabolism, 215
    extracellular matrix metabolism, 215
    gene discovery rationale, 207
    prospects for study, 215
    transforming growth factor-β signaling, 215
    tumor necrosis factor-α signaling, 215
  genetic testing
    adult-onset glaucoma, 262
    approaches, 254
    early-onset glaucoma
      gene mutations, 250
      informed genetic counseling, 250–251
      presymptomatic risk assessment, 251
      surveillance and treatment plans, 251–252
      limitations, 254
      overview, 250
      recommendations, 252
  history taking, 193–194
  natural history, 191–192
  neuroinflammation and retinal ganglion cell loss
    astrocyte and microglia activation, 239–240
    beneficial and damaging effects, 239
    complement cascade, 238–239, 243–245
    immune response, 236
    inflammation signaling, 240–242
    leukocyte transendothelial migration, 238, 242–243
    overview, 235–236
    triggers, 236–238, 240
  novel therapy identification, 254–256
  ophthalmic examination, 194–198
  treatment
    clinical trials, 203–204
    laser therapy, 202
    medical therapy, 200–202
    overview, 197, 200
    surgery, 202, 204
  types, 192
  Glial fibrillary acidic protein (GFAP), glaucoma
    expression, 225, 228
  Glutathione S-transferase (GST), expression in age-
    related macular degeneration, 174
  GNAT2, achromatopsia mutations, 11
  Gonioscopy, glaucoma, 194–195
Index

GPR179, congenital stationary night blindness mutations, 10
GRM6, congenital stationary night blindness mutations, 10
GST. See Glutathione S-transferase
Guanylate cyclase. See GUCY2D
GUCY2D
gene therapy prospects, 327–328
Leber congenital amaurosis mutations
animal models
  GC1/GC2 double knockout mouse, 325–327
  GUCY1*B chicken, 321–323
  knockout mouse, 323–325
  guanylate cyclase functions, 319–320
  patient characterization, 320–321
GUCY2D, Leber congenital amaurosis variants, 44
Gyrate atrophy, OAT mutation, 42, 104

H
Hirschsprung disease, genetic modifiers, 58
HIV. See Human immunodeficiency virus
HK1, retinitis pigmentosa mutations, 35, 106
HMGN1
  age-related macular degeneration susceptibility studies, 163
  variant prioritization, 49
HTRA1
  age-related macular degeneration susceptibility studies, 129, 134, 155–156
  expression in age-related macular degeneration, 172
  induced pluripotent stem cell modeling of mutation, 95
Human immunodeficiency virus (HIV), gene therapy vector for MYO7A delivery, 302

I
IBD. See Identity by descent
Identity by descent (IBD), mapping, 45
IFRD1, genetic modifiers, 58
IMPDH1
  Leber congenital amaurosis mutations, 7
  retinitis pigmentosa mutations, 34–35
Indocyanine green angiopathy, polyploidal choroidal vasculopathy, 117
Induced pluripotent stem cell (iPSC)
cell therapy, 17–18, 91
differentiation, 92
gene therapy
  Fanconi anemia, 418
genome editing, 419–421
  promoters, 419
  prospects, 421–422
timing, 418
  vectors, 417–418
generation, 417
photoreceptor cell differentiation, 416–417
retinal disease modeling
  ABCA4 diseases, 92–93
  age-related macular degeneration, 94–95
  BEST1 mutation, 94
  MAK mutation, 93
  overview, 92
  prospects, 95–96
  USH2A mutation, 93–94
RNA-Seq studies, 83
iPSC. See Induced pluripotent stem cell
IQCB1
  genetic modifiers, 65
  inherited retinal degeneration, 46
IRX3, genetic modifiers, 58

J
Joubert syndrome
gene mutations, 46
retinitis pigmentosa, 6–7

L
Latanoprost, glaucoma management, 201
LCA. See Leber congenital amaurosis
Leber congenital amaurosis (LCA)
aminal models of RPGRIP1 mutation, 365–367
  clinical features, 7–8, 363
  epidemiology, 7
  gene therapy
genomic. See RPE65; RPGRIP1
  overview, 12–13
GUCY2D mutations
animal models
  GC1/GC2 double knockout mouse, 325–327
  GUCY1*B chicken, 321–323
  knockout mouse, 323–325
  gene therapy prospects, 327–328
  guanylate cyclase functions, 319–320
  patient characterization, 320–321
Leber’s hereditary optic neuropathy. See Primary optic neuropathy
Lentivirus gene therapy vectors. See also specific viruses
  ABCA4 delivery, 293–294
  MYO7A delivery, 302–303
Leukocyte transendothelial migration, glaucoma, 238, 242–243
Linkage analysis
  age-related macular degeneration susceptibility studies, 157
  genetic modifier identification, 60
  inherited retinal degeneration, 45–46
LMX1B, glaucoma mutations, 209

442

© 2015 by Cold Spring Harbor Laboratory Press. All rights reserved.
L opsin, gene therapy in dichromatic primates, 402–405

LOXL1
- genetic testing, 252
- glaucoma mutations, 213

LRIT3, congenital stationary night blindness mutations, 10

LTBP2
- genetic testing, 250–252
- glaucoma mutations, 208–209, 215

Lutein
- age-related macular degeneration management, 118
- retinal degeneration management, 11

M

MAK
- induced pluripotent stem cell modeling of mutation, 93
- variant prioritization, 49

MBL2, genetic modifiers, 58

MELAS, pigmentary retinopathy, 102

MERTK, gene therapy, 13

MFSD8, mutation effects, 106

Mitochondrial disease, pigmentary retinopathy, 102

Mtap1a, genetic modifiers, 66

MTTP, Bassen–Kornzweig syndrome mutation, 103

MVK, retinitis pigmentosa mutations, 46

MYO7A
- gene therapy
  - adeno-associated virus vectors
    - dual vectors, 304–305
    - single vectors, 303–304
  - equine infectious anemia virus vectors, 302–303
  - human immunodeficiency virus vectors, 302
  - prospects, 306, 429
  - splice variants, 305–306
  - inherited retinal degeneration, 46
  - mouse mutants, 299–302

MYOC
- genetic testing, 250–252
- glaucoma mutations, 210, 215
- therapeutic targeting, 255

N

Neuronal ceroid lipofuscinosis, clinical features and gene mutations, 103–104

Next generation sequencing (NGS). See also RNA-Seq autosomal dominant retinitis pigmentosa genetic testing, 28, 30–31, 36
- clinical applications in ophthalmology, 78–79
- exome sequencing, 44–45
- overview, 78
- targeted sequencing, 44

NGS. See Next generation sequencing

Nilvadipine, retinal degeneration management, 16

NOD-like receptors, glaucoma
- neuroinflammation role, 237

Normal-tension glaucoma. See Glaucoma

NPHe1, genetic modifiers, 62

NR2E3, retinitis pigmentosa mutations, 5

NRL, retinitis pigmentosa mutations, 5

NYX, congenital stationary night blindness mutations, 10

O

OAT, gyrate atrophy mutation, 42, 104

OCT. See Optical coherence tomography

OFD1, Joubert syndrome mutations, 46

OPAL, genetic testing, 252–254

OPTN
- genetic testing, 250–252
- glaucoma mutations, 211, 215

Optic nerve disorders. See Glaucoma; Primary optic neuropathy

Optical coherence tomography (OCT)
- achromatopsia findings, 11
- chorioidal neovascularization, 115–116
- congenital stationary night blindness findings, 10
- gene therapy studies, 430
- glaucoma, 197–198
- patient selection for retinal degeneration treatment, 18
- reticular pseudodrusen, 112
- retinitis pigmentosa findings, 2–3
- Stargardt disease findings, 8
- X-linked retinoschisis, 335

OPTN
- genetic testing, 250–252
- glaucoma mutations, 211, 215

Optogenetics, vision restoration, 16–17

OTUD4, genetic modifiers, 63

OTX2, Leber congenital amaurosis mutations, 7

P

Palmitoyl protein thioesterase (PPT), neuronal ceroid lipofuscinosis role, 103

PAX6
- genetic testing, 250–252
- glaucoma mutations, 209

PCV. See Polyploidal chorioidal vasculopathy

PDE-β, retinitis pigmentosa mutations, 5

PDE6A, retinitis pigmentosa mutations, 5

PDE6B, retinitis pigmentosa mutations, 5

PDE6C, achromatopsia mutations, 11

PDE6H, achromatopsia mutations, 11

PDT. See Photodynamic therapy

PDXD7, genetic modifiers, 65

PED. See Retinal pigment epithelial detachment

PEDE. See Pigment epithelium-derived factor

Pegaptanib, age-related macular degeneration management, 120
Index

Peripherin-2. See PRPH2
PEX7, Refsum disease mutation, 102
Photocoagulation, age-related macular degeneration management, 119
Photodynamic therapy (PDT), age-related macular degeneration management, 120–121
PHYH, Refsum disease mutation, 102
Pigment epithelium-derived factor (PEDF), gene therapy
age-related macular degeneration, 313–314
neuroprotection, 15
PRPH2 diseases, 356
PITX2
  genetic testing, 250–252
  glaucoma mutations, 209
PLEKHA1, age-related macular degeneration susceptibility studies, 129
PLINK, single nucleotide polymorphism analysis, 45
PLS3, genetic modifiers, 63
Polyploidal choroidal vasculopathy (PCV), age-related macular degeneration, 116–117
PPT. See Palmitoyl protein thioesterase
Primary open-angle glaucoma. See Glaucoma
Primary optic neuropathy
  genetic testing
    approaches, 254
    gene mutations, 252–253
    gene therapy candidate identification, 253
    informed genetic counseling, 253
    limitations, 254
    risk assessment, 253
    novel therapy identification, 254–256
    risk factor avoidance, 253
PRPF3, retinitis pigmentosa mutations, 35
PRPF31, retinitis pigmentosa mutations, 30–33, 35
PRPF4, retinitis pigmentosa mutations, 35
PRPF6, retinitis pigmentosa mutations, 35
PRPF8, retinitis pigmentosa mutations, 35
PRPH2
  animal models of mutations, 349–351
  autosomal-dominant retinitis pigmentosa mutations, 348–349
  central areolar choroidal dystrophy mutations, 104
  functional overview, 347–348
  gene therapy
    adeno-associated virus vectors, 352–353
    knockdown therapy, 355
    neuroprotection, 355–356
    plasmid DNA vectors, 353–355
    prospects, 357
    transgene replacement, 351–352
    vascular endothelial growth factor inhibitors, 356–357
  genetic modifiers, 61–62
  retinitis pigmentosa mutations, 5, 31, 33, 35
Pseudoexfoliation syndrome. See Glaucoma

R
Ranibizumab, age-related macular degeneration management, 120–121
RAP. See Retinal angiomatic proliferation
RdCVF. See Rod-derived cone viability factor
RDH12, retinitis pigmentosa mutations, 28
RDS, genetic modifiers, 64
Refsum disease
  clinical features, 102
  hearing loss, 100
REP1
  animal mutant studies, 279–280
  expression and function, 278–279
  functional overview, 10
  gene. See CHM
RET, genetic modifiers, 60, 62
Reticular pseudodrusen. See Drusen
Retina, structure, 90
Retinal angiomatous proliferation (RAP), age-related macular degeneration, 117
Retinal pigment epithelial detachment (PED), choroidal neovascularization, 114–115
Retinal pigment epithelium (RPE), hyperplasia, 116
Retinitis pigmentosa (RP)
  autosomal dominant disease gene mutations. See also PRPH2; RHO
discovery, 28, 30–31
dominant-recessive acting mutations, 35
genetic testing, 28, 30–31, 36
overview, 27–28
pathogenicity, 31–32
prevalence of mutations, 32–35
protein functions, 35
reconciling diagnosis, family history, and molecular findings, 35–36
table, 29–30
classification, 1–2
clinical features, 2–3, 27
epidemiology, 3–4, 27
genetics, 4–5
syndromic/systemic forms, 5–7
treatment
  alternative pharmacotherapy, 15–16
  cell therapy, 17–18
  neuroprotection, 15
  overview, 11
  retinal prosthetics, 16
Retinoschisin. See RS1
RHO
gene therapy
  adeno-associated virus specificity, 389
  clinical prospects, 395–396
  expression levels, 389–390
  photoreceptor rescue, 390–392
Index

RH0 (Continued)

rationale, 388–389
RNA replacement, 392–395
vectors, 389
zinc-finger repressors, 392
genomics studies, 43
retinitis pigmentosa mutations, 4–5, 31, 55, 387–388

RNA-Seq
age-related macular degeneration gene expression studies, 174–176
bioinformatics
alignment of data, 80
differential expression analysis, 80–82
inherited retinal disease models, 82–83
mechanisms, 83–84
next generation library preparation, 79–80
overview, 78–79
retina transcripts, 82

RNF216, genetic modifiers, 63

Rod-derived cone viability factor (RdCVF), 15

ROM1

gene therapy
animal models, 415
clinical trials
outcome measures, 268
Phase I/II trials, 260, 263–265
Phase II, 265
Phase III, 265
table, 261–262
overview, 259–260, 427–428, 430–431
prevention of retina degradation, 266–267
prospects, 269–270
subretinal injection safety, 267–268

RPE. See Retinal pigment epithelium

RPE65

functional overview, 260–261
gene therapy
animal models, 415
clinical trials
outcome measures, 268
Phase I/II trials, 260, 263–265
Phase II, 265
Phase III, 265
table, 261–262
overview, 259–260, 427–428, 430–431
prevention of retina degradation, 266–267
prospects, 269–270
subretinal injection safety, 267–268

genetic modifiers, 68
retinitis pigmentosa mutations, 28

RPGR
functional overview, 372
mutation effects, 105
retinitis pigmentosa mutations, 32–35
X-linked retinoschisis
animal models
dog, 373–376
mouse, 373
gene therapy
dog studies, 376–383
onset prevention, 377
photoreceptor rescue, 377–383

prospects, 383
vectors, 376
mutations and phenotypes, 371–373
neuroprotection studies, 376

RPGRIP1
animal models of mutation, 365–367
functional overview, 364–365
genre therapy prospects, 367–368
Leber congenital amaurosis mutations, 363

RPGRIP1L, genetic modifiers, 59, 64–65

RPIL1, variant prioritization, 49

RSL
developmental expression, 336
functional overview, 335
genre therapy
administration route, 339, 341
efficacy, 341–343
overview, 14
prospects, 343
vectors, 337–339
mouse mutants, 336–337, 340

X-linked retinoschisis mutations, 8, 335–336

S

SAA. See Serum Amyloid A
SAG, retinitis pigmentosa mutations, 5
SAGE. See Serial analysis of gene expression
SCA. See Spinocerebellar ataxia
Senior–Løken syndrome

gene mutations, 46
retinitis pigmentosa, 5
Serial analysis of gene expression (SAGE), overview, 77
Serum Amyloid A (SAA), glaucoma expression, 224
sFL T01, gene therapy for age-related macular degeneration, 311–312

SIX1, glaucoma mutations, 211–213

SIX6, glaucoma mutations, 211–213

SMA. See Spinal muscle atrophy

Spinal muscle atrophy (SMA), genetic modifiers, 63
Spinocerebellar ataxia (SCA), genetic modifiers in SCA1, 62

Stargardt disease

ABCA4 mutations, 9, 42, 289
clinical features, 8–9
genre therapy. See ABCA4
STAT3, glaucoma expression, 224

T

TALENs, genome editing, 420–421

TBK1

gene therapy testing, 250–252

glaucoma mutations, 211, 215
Index

TCF8, genetic modifiers, 60
TGF-β. See Transforming growth factor-β
Timolol, glaucoma management, 201
TLRs. See Toll-like receptors
TNF-α. See Tumor necrosis factor-α
Toll-like receptors (TLRs), glaucoma neuroinflammation role, 236–237, 240–241
Trabeculectomy, glaucoma management, 202, 204
Trabeculoplasty, glaucoma management, 202
Transcriptomics. See also RNA-Seq
    genetic modifier identification, 62–63
    inherited retinal degeneration, 47
Transforming growth factor-β (TGF-β)
    glaucoma expression, 222, 227, 229
    signaling and glaucoma, 215
Travoprost, glaucoma management, 201
TRPM1, congenital stationary night blindness
    mutations, 10
TSPAN12, linkage studies, 45
Tumor necrosis factor-α (TNF-α)
    glaucoma expression, 225, 228–229
    signaling and glaucoma, 215, 241

U
USH2A, induced pluripotent stem cell modeling
    of mutation, 93–94
Usher syndrome
    gene mutations, 46
    genetic modifiers, 65
    hearing loss, 100–101
    mouse models, 299–302
MYO7A gene therapy. See MYO7A
    retinitis pigmentosa, 5–6
    types, 100

V
Valproic acid, retinal degeneration
    management, 15
Vascular endothelial growth factor (VEGF)
    inhibitor gene therapy
        age-related macular degeneration, 310–312
        PRPH2 diseases, 356–357
    inhibitor therapy for age-related macular
        degeneration, 120–121
VEGF. See Vascular endothelial growth factor
Vitamin A, retinal degeneration management, 11

W
Whole genome sequencing
    age-related macular degeneration susceptibility
        studies, 158
    inherited retinal degeneration, 47

X
X-linked retinoschisis (XLRS)
    clinical features, 8, 333–335
    epidemiology, 8
    gene and cell biology, 335, 371
    gene therapy. See RPGR; RS1
    genetic modifiers, 68
    management, 335
    mouse models, 336–337, 340
    XLPR dog models. See RPGR
    XLRS. See X-linked retinoschisis

Z
ZNF408, linkage studies, 45